Biosimilar spat erupts again in Europe
This article was originally published in Scrip
Executive Summary
The European biotechnology industry body EuropaBio says that the labeling of biosimilar medicines should make clear whether the data used for their approval were generated for the biosimilar or its reference product, and should include information on the reasons for any extrapolation of indications.